In clinical practice, prostate cancer (PCa) is currently diagnosed by performing prostate-specific antigen (PSA) blood tests and if the PSA serum levels are increased, followed by tissue biopsy and pathological inspection. This evidence concerns the gene KLK3 and Familial prostate cancer.